BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

40 related articles for article (PubMed ID: 35749742)

  • 21. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
    Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
    Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
    Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
    J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
    Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
    J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2.
    Johnson LN; De Moliner E; Brown NR; Song H; Barford D; Endicott JA; Noble ME
    Pharmacol Ther; 2002; 93(2-3):113-24. PubMed ID: 12191604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres.
    Jorda R; Paruch K; Krystof V
    Curr Pharm Des; 2012; 18(20):2974-80. PubMed ID: 22571665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Small-molecule degraders of cyclin-dependent kinase protein: a review.
    Yu B; Du Z; Zhang Y; Li Z; Bian J
    Future Med Chem; 2022 Jan; 14(3):167-185. PubMed ID: 34939427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current progress and novel strategies that target CDK12 for drug discovery.
    Lei P; Zhang J; Liao P; Ren C; Wang J; Wang Y
    Eur J Med Chem; 2022 Oct; 240():114603. PubMed ID: 35868123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 3,5,7-Substituted Pyrazolo[4,3-
    Jorda R; Havlíček L; Peřina M; Vojáčková V; Pospíšil T; Djukic S; Škerlová J; Grúz J; Renešová N; Klener P; Řezáčová P; Strnad M; Kryštof V
    J Med Chem; 2022 Jul; 65(13):8881-8896. PubMed ID: 35749742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
    Teng Y; Lu K; Zhang Q; Zhao L; Huang Y; Ingarra AM; Galons H; Li T; Cui S; Yu P; Oumata N
    Eur J Med Chem; 2019 Dec; 183():111641. PubMed ID: 31514062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
    Ruetz S; Fabbro D; Zimmermann J; Meyer T; Gray N
    Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):1-14. PubMed ID: 12678910
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.